Progress in Alzheimer’s disease research in the last year

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with a prevalence of 5 % after 65 years of age, increasing to about 30 % in people aged 85 years or older. It is characterized by progressive cognitive impairment, including impaired judgment, decision-making and orientation, and in some cases accompanied by psycho behavioral disturbances or language impairment. Herein, we summarize and discuss the main articles describing novel findings in AD published over the last year, including clinical, therapeutic, and research issues.

Cardiovascular Effects of Drugs Used to Treat Alzheimer’s Disease

“…Alzheimers' disease (AD) is the most common form of dementia which is increasing in prevalence as the average age of the population rises. In 2013 it was estimated that 5% of the population over the age of 65 years had AD and that this proportion increased with age such that nearly 30% of the population older than 85 years was affected [1].…”

Flavonoids from Scutellaria attenuate okadaic acid-induced neuronal damage in rats

“…Alzheimer's disease (AD), one of the most common causes of adult dementia, is a neurodegenerative disease characterized by progressive cognitive decline [1]. Although many great achievements have been made in the study of AD over the past 20 years, the pathogenesis of AD is still not completely understood.…”

“…Brain Inj, Early Online:[1][2][3][4][5][6][7] Brain Inj Downloaded from informahealthcare.com by Nyu Medical Center on 07/28/15For personal use only.…”

Alzheimer's disease and chronic periodontitis: Is there an association?

“…1,2 It has been speculated that with the increasing life expectancy and lifestyle changes, one in 85 people would be living with AD by the year 2050. It is the most frequent type of dementia characterized by a progressive decline in memory, thinking, language and learning capacity, which ultimately ends in death.…”

“…More than 37 million people are affected by it globally, with the highest prevalence in the elderly aged ≥65 years. 1,2 It has been speculated that with the increasing life expectancy and lifestyle changes, one in 85 people would be living with AD by the year 2050. 3 The cognitive decline in AD has been related to the formation of synaptotoxic β-amyloid (Aβ) peptide plaques and the neurofibrillary tangles composed of hyperphosphorylated tau proteins, in the regions of the brain associated with advanced cognitive functions.…”